August 2, 2018 5:52pm

… Be ready for next week’s 17 releases

Pre-open indications: 6 hit and 1 miss

Earnings: Alnylam Pharmaceuticals (ALNY +$0.73) reported a Q2 loss of $63.6 M or -$1.61 per share; representing an earnings surprise of -4.55%;  bluebird bio (BLUE +$0.96 to $156.30) crested after its Q2 releases fall in a day’s range of $148.00 to $157.35;

... BioMarin (BMRN +$1.08) reported a loss of $16.8 M or -$0.09 per share, not meeting “Street” expectations although revenue exceeded anticipation ($378.8 M versus Q2/17’s $361.5 M); BioTime’s (NYSEMKT:BTX -$0.04) Q2 net loss was $4.2 million, or ($0.03) per share, compared to a net of $11.7 million, or ($0.11) per share in Q2/17;

... Ultragenyx Pharmaceutical (RARE +$0.24) reported a net loss of $52.7 million, or $1.06 per share, compared with a Q2/17’ $72.9 million, or $1.72 per share while Global Blood Therapeutics’ (GBT +$0.50) Q2 net loss was $40.4 million or -$0.78 compared with $23.9 M or -$0.55 in 2017.

 

Out and about: Juvenescence will purchase, in a single transaction, 14.4 million shares of AgeX Therapeutics from BTX for $43.2 million. 50% of the purchase price will be paid to BioTime in cash and the remaining 50% will be a 2-year convertible/redeemable note with an annual interest rate of 7%, payable at maturity … and BTX drops -$0.04?

 

Consider the end-of-day results as a next day primer!

Never leave an investor uninformed!  Want to know WHY, WHAT and HOW, subscribe!


Members only. Please login.